A double-blind study of cefaclor and amoxycillin in home and hospital-acquired infections.
Eighty-seven patients admitted to hospital for a variety of reasons and who had, or subsequently developed, an infection were treated with either cefaclor or amoxycillin, 150 mg 3-times daily, on a double-blind basis. Two patients were excluded from te final analysis as the infecting organisms would normally be resistant to both antibiotics. Forty (93%) patients treated with cefaclor and 40 (95.2%) treated with amoxycillin responded satisfactorily. Of the patients with a hospital-acquired infection, 93.3% of the cefaclor group and 94.3% of the amoxycillin group responded satisfactorily. The differences between the groups were not significant. A greater number of organisms were sensitive to cefaclor, confirming its broader spectrum of activity. It is concluded that cefaclor is a useful first-line antibiotic which could be particularly useful in hospital-acquired infections.
D000658:Amoxicillin / Q000627:therapeutic use*; D002433:Cefaclor / Q000627:therapeutic use*; D002506:Cephalexin / Q000031:analogs & derivatives*; D003428:Cross Infection / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D008826:Microbial Sensitivity Tests; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002433:Cefaclor; D000658:Amoxicillin; D002506:Cephalexin